Clinical trials: Vasomotor Symptoms
Menopause, Hot Flashes
Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women
The broad goal of this study is to obtain pilot data to determine the tolerability and preliminary efficacy of the non-hormonal agent gabapentin for insomnia symptoms and nighttime vasomotor Symptoms (VMS) when open-label…
- Conditions
- Menopause, Hot Flashes, Vasomotor Disturbance
- Trial name
- NCT02040532
- Testing
- Gabapentin
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Hot Flashes
Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women
Depomed's Gabapentin Extended Release is an investigational, extended release formulation of Gabapentin that is being studied for the treatment of Hot Flashes/Hot Flushes in postmenopausal women
- Trial name
- Breeze3 (NCT01080300)
- Testing
- Gabapentin Extended Release
- Where
- 66 sites in United States
- Volunteers
- 600 people
- Sponsor
- Depomed
Hot Flashes, Menopause
Pilot Study of Stellate Ganglion Injection to Provide Relief From Hot Flushes
This study is being done to determine whether stellate ganglion injection with local anesthetic (the study procedure) can reduce the number and severity of hot flashes in women who have hot flashes.
- Trial name
- NCT00992914
- Testing
- Sympathetic nerve block with 1% lidocaine 1-2 ml, Superficial subcutaneous injection
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Moderate to Severe Vasomotor Symptoms
A Survey About Trade-offs When Choosing Menopause Treatments
This study is an online survey of women in menopause with moderate to severe hot flashes. Menopause, a normal part of life, is the time after a woman's last period. Hot flashes often occur during menopause.
- Trial name
- NCT05300568
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 1,465 people
- Sponsor
- Astellas Pharma Europe Ltd.
Menopause, Blood Pressure
Effect of Different Exercise Modalities on Cardiovascular and Cognitive Response in Postmenopausal Women
Menopause is a natural stage in female aging, increasing cardiometabolic risk and making cardio-neuro-vascular disease (CNVD) the leading cause of mortality in women over 60.
- Conditions
- Menopause, Blood Pressure, Cognitive Decline
- Trial name
- WOMEN-EX-MOD (NCT06533982)
- Testing
- High intensity interval exercise session, Isometric neuromuscular exercise session
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Poitiers
Hot Flashes, Menopause
Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women.
Hot flashes can be a disturbing symptom of menopause. Prescription medications are commonly used for symptom relief. Several non-prescription therapies are under investigation.
- Trial name
- NCT00599456
- Testing
- Omega 3 fatty acid vitamins
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Christiana Care Health Services
Menopause Syndrome
Effects of Connective Tissue Manipulation on Menopausal Symptoms
Menopause is defined as the permanent cessation of menstruation as a result of the loss of ovarian follicular function. This process involves some bothersome physical and psychological climacteric symptoms.
- Trial name
- NCT05293860
- Testing
- Connective tissue manipulation, Superficial massage with the head of the therapeutic ultrasound device
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people
- Sponsor
- Hacettepe University
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer